D. Boral Capital Reaffirms “Buy” Rating for FibroBiologics (NASDAQ:FBLG)

FibroBiologics (NASDAQ:FBLG)‘s stock had its “buy” rating reaffirmed by investment analysts at D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $15.00 price objective on the stock.

Several other equities research analysts also recently commented on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of FibroBiologics in a research note on Wednesday, October 8th. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective on shares of FibroBiologics in a report on Friday. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, FibroBiologics presently has an average rating of “Hold” and an average target price of $10.00.

FibroBiologics Stock Down 1.4%

FibroBiologics stock opened at $0.24 on Tuesday. FibroBiologics has a twelve month low of $0.22 and a twelve month high of $2.34. The company has a market cap of $15.96 million, a PE ratio of -0.50 and a beta of -0.54. The company’s 50-day moving average price is $0.30 and its 200-day moving average price is $0.48.

FibroBiologics (NASDAQ:FBLG) last posted its quarterly earnings data on Friday, October 31st. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.03). As a group, sell-side analysts expect that FibroBiologics will post -0.53 earnings per share for the current fiscal year.

Insider Buying and Selling at FibroBiologics

In related news, General Counsel Ruben A. Garcia acquired 140,000 shares of the stock in a transaction on Thursday, December 11th. The shares were purchased at an average price of $0.34 per share, for a total transaction of $47,600.00. Following the purchase, the general counsel directly owned 140,000 shares in the company, valued at approximately $47,600. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 13.00% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Ethos Financial Group LLC increased its holdings in FibroBiologics by 100.0% in the second quarter. Ethos Financial Group LLC now owns 48,848 shares of the company’s stock valued at $30,000 after buying an additional 24,424 shares in the last quarter. XTX Topco Ltd grew its holdings in FibroBiologics by 160.0% in the second quarter. XTX Topco Ltd now owns 45,945 shares of the company’s stock valued at $29,000 after purchasing an additional 28,276 shares during the period. Cascade Financial Partners LLC increased its position in shares of FibroBiologics by 11.7% during the second quarter. Cascade Financial Partners LLC now owns 290,581 shares of the company’s stock worth $181,000 after acquiring an additional 30,500 shares during the last quarter. AQR Capital Management LLC bought a new position in FibroBiologics during the 1st quarter worth $29,000. Finally, Cerity Partners LLC raised its position in FibroBiologics by 37.2% in the second quarter. Cerity Partners LLC now owns 128,109 shares of the company’s stock worth $80,000 after acquiring an additional 34,702 shares in the last quarter.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.